Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
| Autor: | Le Tourneau, C., Becker, H., Claus, R., Elez, E., Ricci, F., Fritsch, R., Silber, Y., Hennequin, A., Tabernero, J., Jayadeva, G., Luedtke, D., He, M., Isambert, N. |
|---|---|
| Zdroj: | In ESMO Open October 2022 7(5) |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|